{"id":"cyclosporine-ophthalmic","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation or burning"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Transient blurred vision"}]},"_chembl":{"chemblId":"CHEMBL406352","moleculeType":"Small molecule","molecularWeight":"1202.63"},"_dailymed":{"setId":"0a60fccf-7e1b-44fe-e063-6394a90aadd5","title":"VEVYE (CYCLOSPORINE OPHTHALMIC SOLUTION) SOLUTION/ DROPS [HARROW EYE, LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cyclosporine binds to cyclophilin and inhibits calcineurin, a phosphatase required for T-cell activation and IL-2 production. In ophthalmic formulation, it reduces ocular surface inflammation by decreasing T-lymphocyte infiltration and pro-inflammatory cytokine release, thereby improving tear production and reducing dry eye symptoms.","oneSentence":"Cyclosporine is a calcineurin inhibitor that suppresses T-cell activation and reduces inflammatory cytokine production in the eye.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:31:29.650Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dry eye disease (keratoconjunctivitis sicca)"},{"name":"Ocular surface inflammation"}]},"trialDetails":[{"nctId":"NCT07224529","phase":"PHASE4","title":"Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-04-01","conditions":"Meibomian Gland Dysfunction (MGD)","enrollment":48},{"nctId":"NCT07463950","phase":"PHASE4","title":"A Non-interventional Study to Evaluate the Anti-inflammatory Effects and the Clinical Efficacy of Topical Water Free Cyclosporin 0.1% Eye Drops in Patients With Dry Eye Disease and Associated Ocular Surface Inflammation Non-responding to Artificial Tears: the FOCUS Study","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2026-01-20","conditions":"Dry Eye Disease (DED)","enrollment":25},{"nctId":"NCT05692739","phase":"PHASE4","title":"Clinical Trial To Determine The Effectiveness And Safety Of Topical Insulin In Dry Eye","status":"COMPLETED","sponsor":"Barbara Burgos Blasco","startDate":"2022-10-19","conditions":"Dry Eye, Insulin","enrollment":116},{"nctId":"NCT07397936","phase":"PHASE4","title":"Rebamipide Versus Diquafosol and Cyclosporine for Perioperative Dry Eye in Cataract Surgery","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2024-08-01","conditions":"Dry Eye Disease (DED), Cataract","enrollment":55},{"nctId":"NCT07368595","phase":"PHASE4","title":"Comparison of Conjunctival Goblet Cell Density in Dry Eye Patients Treated With Cyclosporine 0.1% Dissolved in Perfluorobutylpentane (Vevye®) or Generic 0.05% Cyclosporine Emulsion for 8 Weeks","status":"NOT_YET_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2026-04-01","conditions":"Dry Eye Disease (DED)","enrollment":60},{"nctId":"NCT05136170","phase":"PHASE3","title":"Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease","status":"COMPLETED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2022-01-27","conditions":"Dry Eye Disease","enrollment":85},{"nctId":"NCT04795752","phase":"NA","title":"Safety And Effectiveness Of The TearCare® System In The Treatment Of The Signs And Symptoms Of Dry Eye Disease (SAHARA)","status":"COMPLETED","sponsor":"Sight Sciences, Inc.","startDate":"2021-04-28","conditions":"Dry Eye, Meibomian Gland Dysfunction","enrollment":345},{"nctId":"NCT07239128","phase":"EARLY_PHASE1","title":"Photobiomodulation in Combination With Topical Cyclosporine A or Tacrolimus","status":"COMPLETED","sponsor":"University of Seville","startDate":"2024-05-01","conditions":"Dry Eye Disease (DED)","enrollment":160},{"nctId":"NCT06981104","phase":"NA","title":"Tear Film Stability and Improvement of Asthenopia: Efficacy Observation of 0.05% Cyclosporine in Dry Eye Patients With Short BUT","status":"COMPLETED","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-11-18","conditions":"Dry Eye Disease (DED), Asthenopia","enrollment":60},{"nctId":"NCT07234318","phase":"","title":"Non-interventional Study to Evaluate the Anti-inflammatory Effects and the Clinical Efficacy of Topical Water Free Cyclosporin 0.1% Eye Drops in Patients With Dry Eye Disease and Associated Ocular Surface Inflammation Non-responding to Artificial Tears","status":"NOT_YET_RECRUITING","sponsor":"Laboratoires Thea","startDate":"2025-12-15","conditions":"Dry Eye Disease (DED)","enrollment":25},{"nctId":"NCT07025811","phase":"PHASE4","title":"A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-07-09","conditions":"Dry Eye Disease","enrollment":350},{"nctId":"NCT06658002","phase":"PHASE3","title":"Fungal Ulcer Treatment Augmented With Natamycin and Cyclosporine A","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-09-01","conditions":"Fungal Keratitis, Corneal Ulcer","enrollment":150},{"nctId":"NCT06903884","phase":"PHASE3","title":"3% Diquafosol Ophthalmic Solution for Active Moderate-to-Severe Vernal Keratoconjunctivitis","status":"NOT_YET_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2025-12-30","conditions":"Vernal Keratoconjunctivitis","enrollment":94},{"nctId":"NCT07171710","phase":"NA","title":"Efficacy of 0.05% Cyclosporine A Eye Drops Combined With Absorbable Tear Duct Plugs in the Treatment of Dry Eye in Sjögren's Syndrom","status":"ENROLLING_BY_INVITATION","sponsor":"Tianjin Eye Hospital","startDate":"2024-03-01","conditions":"Dry Eye Disease","enrollment":30},{"nctId":"NCT07169695","phase":"PHASE2","title":"A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal Keratoconjunctivitis","status":"NOT_YET_RECRUITING","sponsor":"Laboratoires Thea","startDate":"2026-03-02","conditions":"Moderate to Severe Vernal Keratoconjunctivitis","enrollment":120},{"nctId":"NCT07089511","phase":"NA","title":"Cord Blood Platelet Poor Plasma Eye Drops","status":"RECRUITING","sponsor":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","startDate":"2025-03-11","conditions":"Dry Eye","enrollment":100},{"nctId":"NCT06936462","phase":"NA","title":"Potential Role of Ocular Surface Microbiome in Dry Eye: Microbial Interactions and Symptom Alleviation","status":"COMPLETED","sponsor":"Hallym University Kangnam Sacred Heart Hospital","startDate":"2020-01-20","conditions":"Dry Eye Syndrome (DES)","enrollment":50},{"nctId":"NCT06329661","phase":"PHASE4","title":"A Clinical Trial to Evaluate the Corneal Endothelial Health of DED Subjects Treated With Cyclosporine","status":"COMPLETED","sponsor":"Novaliq GmbH","startDate":"2024-04-22","conditions":"Dry Eye Disease","enrollment":204},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT06766357","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Cyclosporin Ophthalmic Gel in Subjects With Moderate to Severe Dry Eye Disease","status":"RECRUITING","sponsor":"Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.","startDate":"2025-04-03","conditions":"Moderate to Severe Dry Eye","enrollment":360},{"nctId":"NCT04734197","phase":"PHASE2","title":"A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Surface Ophthalmics, Inc.","startDate":"2021-01-11","conditions":"Dry Eye Disease","enrollment":349},{"nctId":"NCT06898853","phase":"NA","title":"The Effect of 0.1% Topical Ciclosporin A for 12-weeks on the Eye Surface Immune Cells in Dry Eyes","status":"NOT_YET_RECRUITING","sponsor":"The University of New South Wales","startDate":"2025-05-01","conditions":"Dry Eye Disease (DED)","enrollment":60},{"nctId":"NCT06876116","phase":"PHASE4","title":"Once-daily Fluorometholone vs Twice-daily Cyclosporine in Dry Eye Disease","status":"COMPLETED","sponsor":"Korea University Anam Hospital","startDate":"2022-09-01","conditions":"Dry Eye Disease (DED)","enrollment":32},{"nctId":"NCT06824844","phase":"PHASE4","title":"The Effect of 0.05% CsA Eye Drops on Diabetic Patients with Dry Eye Disease","status":"COMPLETED","sponsor":"Peking University Third Hospital","startDate":"2021-12-02","conditions":"Dry Eye","enrollment":60},{"nctId":"NCT04918823","phase":"PHASE1, PHASE2","title":"Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% in a PROSE Device","status":"COMPLETED","sponsor":"Boston Sight","startDate":"2021-07-15","conditions":"Ocular Surface Disease","enrollment":10},{"nctId":"NCT06624384","phase":"PHASE1","title":"Efficacy and Safety of Topical Cyclosporine 0.05% and Lifitgrast on the Ocular Surface Symptom After Photorefractive Keratectomy in Feiz Hospital, Isfahan, 2024","status":"NOT_YET_RECRUITING","sponsor":"Mohsen Pourazizi","startDate":"2024-10-30","conditions":"Ocular Surface Symptom, Ocular Surface Disease, Eye Pain","enrollment":150},{"nctId":"NCT05743764","phase":"PHASE3","title":"HU007 in Patients with Dry Eye Syndrome","status":"COMPLETED","sponsor":"Huons Co., Ltd.","startDate":"2023-03-23","conditions":"Dry Eye Disease","enrollment":328},{"nctId":"NCT04144413","phase":"PHASE3","title":"3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin)","status":"COMPLETED","sponsor":"Santen SAS","startDate":"2019-05-31","conditions":"Dry Eye Disease With Severe Keratitis","enrollment":350},{"nctId":"NCT05957211","phase":"NA","title":"Improving Drop Instillation Comfort of a Cyclosporine A Solution","status":"COMPLETED","sponsor":"University of Waterloo","startDate":"2023-05-19","conditions":"Dry Eye Disease","enrollment":40},{"nctId":"NCT05720715","phase":"PHASE4","title":"Clinical Outcomes of Cyclosporine Eye Drops in Management of Herpetic Keratitis","status":"COMPLETED","sponsor":"Farwaniya Hospital","startDate":"2022-01-01","conditions":"Outcomes of Cyclosporine Eye Drops in Herpetic Keratitis","enrollment":30},{"nctId":"NCT06482177","phase":"PHASE4","title":"The COAT Trial: Cequa's Onset of Action Trial","status":"COMPLETED","sponsor":"Research Insight LLC","startDate":"2023-10-12","conditions":"Dry Eye","enrollment":52},{"nctId":"NCT06392438","phase":"PHASE3","title":"Cyclosporine and Intense Pulsed Light for Dry Eye in Contact Lens Users","status":"RECRUITING","sponsor":"Université de Sherbrooke","startDate":"2024-04-25","conditions":"Dry Eye, Contact Lens Complication","enrollment":44},{"nctId":"NCT03237936","phase":"PHASE4","title":"Effect of IKERVIS® Eye Drops Once Daily on the Quality of Vision in Dry Eye Disease Patients With Severe Keratitis","status":"COMPLETED","sponsor":"Santen SAS","startDate":"2017-03-28","conditions":"Keratitis","enrollment":17},{"nctId":"NCT04835623","phase":"PHASE4","title":"CEQUA for Sjogren's Syndrome Dry Eye","status":"COMPLETED","sponsor":"Center for Ophthalmic and Vision Research, LLC","startDate":"2021-06-21","conditions":"Dry Eye, Dry Eye Syndromes, Sjogren's Syndrome","enrollment":50},{"nctId":"NCT06348602","phase":"PHASE1, PHASE2","title":"Evaluation of Safety & Efficacy for the Prevention of Ocular GVHD With Ophthalmic Tacrolimus vs Cyclosporine in Allo-HSCT","status":"RECRUITING","sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","startDate":"2023-08-01","conditions":"Ocular Graft-versus-host Disease","enrollment":60},{"nctId":"NCT05184517","phase":"EARLY_PHASE1","title":"A Feasibility Study to Evaluate the Tolerability of Oph1 Compared to Restasis in Healthy Volunteers","status":"COMPLETED","sponsor":"OphRx Ltd.","startDate":"2023-01-23","conditions":"Dry Eye Syndromes","enrollment":20},{"nctId":"NCT04357795","phase":"PHASE4","title":"Effect of Cequa™ in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2020-06-29","conditions":"Dry Eye Disease","enrollment":135},{"nctId":"NCT05733624","phase":"PHASE2","title":"Clinical Trial to Evaluate the Safety and Efficacy of SCAI-001 Compared to Restasis","status":"COMPLETED","sponsor":"SCAI Therapeutics","startDate":"2023-01-05","conditions":"Dry Eye Syndromes","enrollment":116},{"nctId":"NCT04515329","phase":"PHASE4","title":"Tear Film Markers in Dry Eye Syndrome","status":"WITHDRAWN","sponsor":"Vishal Jhanji","startDate":"2023-12-08","conditions":"Dry Eye","enrollment":""},{"nctId":"NCT04362670","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-CSI in Subjects With Dry Eye Disease.","status":"COMPLETED","sponsor":"Ocular Therapeutix, Inc.","startDate":"2020-04-23","conditions":"Dry Eye Disease","enrollment":153},{"nctId":"NCT05627947","phase":"PHASE1","title":"Comparison Between Topical Mitomycin C and Cyclosporine","status":"COMPLETED","sponsor":"Egymedicalpedia","startDate":"2021-01-01","conditions":"Pterygium","enrollment":57},{"nctId":"NCT04523142","phase":"PHASE3","title":"CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease in Subjects Who Completed CYS-004","status":"COMPLETED","sponsor":"Novaliq GmbH","startDate":"2021-01-04","conditions":"Dry Eye Disease (DED)","enrollment":202},{"nctId":"NCT04555694","phase":"PHASE4","title":"Comparing Treatment of Dry Eye With Intracanalicular Dexamethasone, Restasis, and/or Lotemax","status":"COMPLETED","sponsor":"Thomas Chester, OD","startDate":"2020-10-01","conditions":"Dry Eye","enrollment":30},{"nctId":"NCT06043908","phase":"PHASE4","title":"The Effect of 0.05% CsA Eye Drops on Post-refractive Surgery Dry Eye","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2022-08-31","conditions":"Dry Eye","enrollment":60},{"nctId":"NCT06013436","phase":"","title":"AST Combined With 0.05% Cyclosporin Eye Drop Improve Corneal Nerve Density in Patients With SS Dry Eye","status":"COMPLETED","sponsor":"Chengdu University of Traditional Chinese Medicine","startDate":"2022-06-01","conditions":"Sjogren's Syndrome, Dry Eye, Ocular Surface Disease","enrollment":30},{"nctId":"NCT00816413","phase":"PHASE1, PHASE2","title":"Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer","status":"WITHDRAWN","sponsor":"University of Nebraska","startDate":"2008-09","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":""},{"nctId":"NCT05928754","phase":"NA","title":"Prospective CoHoRt Of Non-infectious Intermediate, pOsterior or panuveitiS","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts","startDate":"2023-09","conditions":"Non-infectious Uveitis","enrollment":2000},{"nctId":"NCT00335114","phase":"NA","title":"Efficacy of Cyclosporine Ophthalmic Emulsion in the Treatment of Dry Eye Syndrome in Contact Lens Wearers","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2005-11","conditions":"Contact Lens Wearers With Dry Eye Syndrome","enrollment":40},{"nctId":"NCT04735510","phase":"PHASE3","title":"Novel Use of Restasis and PROSE Devices","status":"WITHDRAWN","sponsor":"Boston Sight","startDate":"2021-05","conditions":"Ocular Surface Disease","enrollment":""},{"nctId":"NCT05771012","phase":"NA","title":"Topical Cyclosporin A 0.05% Eye Drops for Management of Symptomatic Acquired Punctal Stenosis. A Prospective, Controlled Clinical Study.","status":"COMPLETED","sponsor":"Farwaniya Hospital","startDate":"2021-01-01","conditions":"Management of Punctal Stenosis","enrollment":42},{"nctId":"NCT04523129","phase":"PHASE3","title":"ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)","status":"COMPLETED","sponsor":"Novaliq GmbH","startDate":"2020-12-05","conditions":"Dry Eye Disease","enrollment":834},{"nctId":"NCT04812951","phase":"EARLY_PHASE1","title":"Cyclosporine 0.1% Eye Drops as Prophylactic Treatment In Cataract Surgery","status":"COMPLETED","sponsor":"Campus Bio-Medico University","startDate":"2021-02-17","conditions":"Ocular Surface Disease, Ocular Inflammation","enrollment":101},{"nctId":"NCT05322148","phase":"PHASE3","title":"Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization","status":"COMPLETED","sponsor":"Research Insight LLC","startDate":"2022-06-03","conditions":"Dry Eye","enrollment":59},{"nctId":"NCT03292809","phase":"PHASE2, PHASE3","title":"CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)","status":"COMPLETED","sponsor":"Novaliq GmbH","startDate":"2017-10-19","conditions":"Dry Eye Disease","enrollment":328},{"nctId":"NCT05605314","phase":"","title":"Clinical Cohort Study in Patients With Different Subtypes of Primary Sjogren Syndrome Related Dry Eye","status":"RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2021-01-01","conditions":"Dry Eye","enrollment":500},{"nctId":"NCT04172961","phase":"PHASE4","title":"Clinical Efficacy of Two Topical Dry Eye Drops for Central Corneal Stain Clearing Over 90 Days","status":"UNKNOWN","sponsor":"Toyos Clinic","startDate":"2020-02-01","conditions":"Dry Eye","enrollment":100},{"nctId":"NCT02688556","phase":"PHASE3","title":"Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2016-02","conditions":"Keratoconjunctivitis Sicca","enrollment":745},{"nctId":"NCT04673604","phase":"NA","title":"From Preserved, to Preservative-free Cyclosporine 0.1% Enhanced Triple Glaucoma Therapy","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2018-05-06","conditions":"Glaucoma, Ocular Surface Disease","enrollment":42},{"nctId":"NCT04127851","phase":"PHASE4","title":"Evaluating HA 0.15% Compared With Cyclosporine 0.05%, and Efficacy of Combination Therapy in Dry Eye Disease Patients","status":"COMPLETED","sponsor":"Taejoon Pharmaceutical Co., Ltd.","startDate":"2019-11-12","conditions":"Dry Eye, Dry Eye Syndromes","enrollment":438},{"nctId":"NCT04426240","phase":"PHASE4","title":"The Effect of Cyclosporin Before Cataract Surgery","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2020-08-03","conditions":"Dry Eye Syndromes","enrollment":40},{"nctId":"NCT05353101","phase":"PHASE1","title":"Cyclosporine 0.05% Eye Drops for Vernal Keratoconjunctivitis Trial","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2020-07-01","conditions":"Vernal Keratoconjunctivitis, Cyclosporine 0.05% Eye Drops","enrollment":48},{"nctId":"NCT01751126","phase":"PHASE3","title":"Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal Keratoconjunctivitis","status":"COMPLETED","sponsor":"Santen SAS","startDate":"2013-04-29","conditions":"Vernal Keratoconjunctivitis","enrollment":169},{"nctId":"NCT05294666","phase":"PHASE4","title":"Evaluation of 0.05% CsA and 0.1% FK506 Eye Drops in Ocular GVHD Treatment","status":"COMPLETED","sponsor":"Peking University Third Hospital","startDate":"2020-04-01","conditions":"Graft Versus Host Disease in Eye","enrollment":89},{"nctId":"NCT05245604","phase":"PHASE3","title":"Evaluating the Efficacy and Safety of TJO-087 in Moderate to Severe Dry Eye Disease Patients","status":"UNKNOWN","sponsor":"Taejoon Pharmaceutical Co., Ltd.","startDate":"2020-06-19","conditions":"Dry Eye Syndrome","enrollment":182},{"nctId":"NCT05131152","phase":"NA","title":"Microvascular and Inflammatory Responses of 0.05 Cyclosporine Eye Drop (II) in Treatment of Dry Eye","status":"UNKNOWN","sponsor":"Zhongshan Ophthalmic Center, Sun Yat-sen University","startDate":"2021-12-01","conditions":"Dry Eye","enrollment":100},{"nctId":"NCT02015351","phase":"NA","title":"Intravitreal Bevacizumab for the Treatment of CNV in VKH Disease - A Prospective Study","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2012-09","conditions":"Choroidal Neovascularization","enrollment":9},{"nctId":"NCT00328653","phase":"PHASE2, PHASE3","title":"Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (VKC)","status":"COMPLETED","sponsor":"Santen SAS","startDate":"2006-05","conditions":"Conjunctivitis, Vernal","enrollment":118},{"nctId":"NCT05076084","phase":"","title":"Evaluation of the Efficacy and Safety of Tacrolimus Drops in Children With Vernal Keratoconjunctivitis","status":"COMPLETED","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","startDate":"2021-10-19","conditions":"Vernal Keratoconjunctivitis","enrollment":15},{"nctId":"NCT04101578","phase":"","title":"Clinical Prognosis and Progression of Myasthenia Gravis Patients","status":"UNKNOWN","sponsor":"Da, Yuwei, M.D.","startDate":"2017-02-08","conditions":"Myasthenia Gravis","enrollment":2000},{"nctId":"NCT03597139","phase":"PHASE2","title":"Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis® in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Aurinia Pharmaceuticals Inc.","startDate":"2018-08-13","conditions":"Dry Eye","enrollment":100},{"nctId":"NCT04492878","phase":"PHASE4","title":"Efficacy and Safety of Ikervis Under Controlled Environmental Conditions Environment","status":"COMPLETED","sponsor":"Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA","startDate":"2020-02-04","conditions":"Dry Eye, Dry Eye Syndromes, Severe Keratitis","enrollment":25},{"nctId":"NCT04597762","phase":"NA","title":"Effect of Ciclosporin Eyedrops on Sjögren Syndrome","status":"COMPLETED","sponsor":"Hospital Hietzing","startDate":"2020-08-31","conditions":"Dry Eye Syndromes","enrollment":12},{"nctId":"NCT04342988","phase":"PHASE4","title":"Effect of Cequa Treatment on Accuracy of Pre-operative Biometry & Higher Order Aberrations in Dry Eye Patients Undergoing Cataract Surgery","status":"COMPLETED","sponsor":"Research Insight LLC","startDate":"2020-04-08","conditions":"Dry Eye Syndromes","enrollment":74},{"nctId":"NCT04775303","phase":"PHASE4","title":"A Clinical Trial to Evaluate the Clinical Efficacy of Cyclosporine 0.1% (Ikervis®) for Moderate to Severe Dry Eye Patients. (IKE-03-SWITCHING)","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2020-09-25","conditions":"Moderate to Severe Dry Eye","enrollment":90},{"nctId":"NCT03287635","phase":"PHASE4","title":"Clinical Efficacy of H.P. Acthar Gel 80 U/ml to Improve the Signs and Symptoms in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Toyos Clinic","startDate":"2018-07-01","conditions":"Dry Eye Disease","enrollment":19},{"nctId":"NCT04714099","phase":"PHASE3","title":"Topical Cyclosporine A for the Treatment of Dry Eye: A Randomized Clinical Study","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2015-01-01","conditions":"Dry Eye","enrollment":40},{"nctId":"NCT04705584","phase":"NA","title":"Topical Immuonosuppressant Drugs in Spring Catarrh","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2021-01","conditions":"Vernal Keratoconjunctivitis","enrollment":180},{"nctId":"NCT04637633","phase":"PHASE2, PHASE3","title":"Topical Cyclosporine-A for Management of Epiphora","status":"COMPLETED","sponsor":"Farwaniya Hospital","startDate":"2020-08-15","conditions":"Epiphora","enrollment":12},{"nctId":"NCT04636918","phase":"PHASE4","title":"Ikervis for DED Due to GVHD Post Allo-HSCT","status":"UNKNOWN","sponsor":"Singapore Eye Research Institute","startDate":"2019-11-28","conditions":"Leukemia (Both ALL and AML), MDS-EB-1","enrollment":40},{"nctId":"NCT02004067","phase":"PHASE4","title":"Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2013-01","conditions":"Primary Sjogren Syndrome, Secondary Sjogren Syndrome, Aqueous Deficient Dry Eye Disease","enrollment":100},{"nctId":"NCT04384991","phase":"PHASE3","title":"HU007 Eye Drops in Patients With Dry Eye Syndrome","status":"COMPLETED","sponsor":"Huons Co., Ltd.","startDate":"2019-05-03","conditions":"Dry Eye Syndromes","enrollment":216},{"nctId":"NCT03461575","phase":"PHASE3","title":"Efficacy and Safety of HU007 Eye Drops in Patients With Dry Eye Syndrome","status":"COMPLETED","sponsor":"Huons Co., Ltd.","startDate":"2018-01-22","conditions":"Dry Eye Syndrome","enrollment":209},{"nctId":"NCT04376970","phase":"PHASE4","title":"Treatment of Corneal Infiltrates Secondary to Epidemic Keratoconjunctivitis","status":"COMPLETED","sponsor":"Military Hospital of Tunis","startDate":"2017-04-01","conditions":"Adenoviral Keratoconjunctivitis","enrollment":51},{"nctId":"NCT02199964","phase":"NA","title":"The Effects of Cyclosporin A in a Low Humidity Environment, on the Ocular Surface","status":"TERMINATED","sponsor":"Baylor College of Medicine","startDate":"2014-03","conditions":"Dry Eye","enrollment":4},{"nctId":"NCT02617667","phase":"PHASE2","title":"CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)","status":"COMPLETED","sponsor":"Novaliq GmbH","startDate":"2016-01","conditions":"Dry Eye Syndromes","enrollment":207},{"nctId":"NCT01817582","phase":"PHASE2","title":"Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2013-05-17","conditions":"Keratoconjunctivitis Sicca","enrollment":102},{"nctId":"NCT03865888","phase":"PHASE3","title":"Comparing Effect of Topical Tacrolimus 0.03% Versus Cyclosporine 0.05% in Dry Eyes of Secondary Sjogren Syndrome","status":"COMPLETED","sponsor":"Pavly Moawd","startDate":"2018-10-30","conditions":"Dry Eye, Sjogren Syndrome","enrollment":60},{"nctId":"NCT00827255","phase":"","title":"Physician's Evaluation of Cyclosporine Ophthalmic Emulsion 0.05%","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-01","conditions":"Dry Eye Disease","enrollment":35},{"nctId":"NCT02121847","phase":"PHASE4","title":"Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-04-03","conditions":"Dry Eye Syndromes","enrollment":40},{"nctId":"NCT00565669","phase":"NA","title":"Evaluation of Blink Tears and Systane Concomitant With Restasis for the Treatment of Dry Eye Symptoms","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2007-10","conditions":"Dry Eye Syndrome","enrollment":20},{"nctId":"NCT03666884","phase":"PHASE4","title":"The Comparison of 50% AS Versus PFAT+ 0.05 % COE in Severe Dry Eye Syndrome","status":"COMPLETED","sponsor":"Seref istek","startDate":"2015-10-10","conditions":"Dry Eye Syndrome","enrollment":36},{"nctId":"NCT01768312","phase":"PHASE3","title":"Study of Cyclosporine Ophthalmic Soution Group and Cyclosporine Ophthalmic Suspension Group","status":"COMPLETED","sponsor":"Hanlim Pharm. Co., Ltd.","startDate":"2012-08-23","conditions":"Dry Eye Syndromes","enrollment":84},{"nctId":"NCT00167583","phase":"PHASE3","title":"Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet's Disease (INCYTOB)","status":"COMPLETED","sponsor":"University Hospital Tuebingen","startDate":"2004-11","conditions":"Behcet's Disease, Panuveitis, Posterior Uveitis","enrollment":37},{"nctId":"NCT02013791","phase":"PHASE2","title":"Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis® X) in Patients With Dry Eye Disease","status":"TERMINATED","sponsor":"Allergan","startDate":"2014-04-29","conditions":"Dry Eye Syndromes","enrollment":55},{"nctId":"NCT02917512","phase":"PHASE2","title":"Efficacy and Safety Study of HU00701/HU007 Eye Drops in Patients With Dry Eye Syndrome","status":"COMPLETED","sponsor":"Huons Co., Ltd.","startDate":"2016-03","conditions":"Dry Eye Syndrome","enrollment":114},{"nctId":"NCT00987467","phase":"NA","title":"Long-term Topical Cyclosporine for Atopic Keratoconjunctivitis","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2007-08","conditions":"Atopic Keratoconjunctivitis","enrollment":12},{"nctId":"NCT03403023","phase":"NA","title":"Corneal Tear Film Imaging of the Cornea Before and After Restasis Therapy","status":"UNKNOWN","sponsor":"Meir Medical Center","startDate":"2018-01-30","conditions":"Dry Eye Syndrome, Tear Film Insufficiency","enrollment":40},{"nctId":"NCT03395431","phase":"NA","title":"Fingerprick Autologous Blood (FAB) in Severe Dry Eye Disease (DED)","status":"UNKNOWN","sponsor":"Bedford Hospital NHS Trust","startDate":"2018-02","conditions":"Dry Eye Syndromes","enrollment":60},{"nctId":"NCT00102583","phase":"PHASE1","title":"Cyclosporine Implant for Ocular Graft-Versus-Host Disease","status":"COMPLETED","sponsor":"National Eye Institute (NEI)","startDate":"2004-10-14","conditions":"Graft Vs Host Disease","enrollment":4},{"nctId":"NCT00079183","phase":"PHASE2","title":"Sirolimus as Secondary Therapy in Chronic Graft-Versus-Host Disease Not Responding To Prior Treatment","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2002-04","conditions":"Graft Versus Host Disease","enrollment":44}],"_emaApprovals":[],"_faersSignals":[{"count":4,"reaction":"VISION BLURRED"},{"count":3,"reaction":"DIZZINESS"},{"count":2,"reaction":"CONDITION AGGRAVATED"},{"count":2,"reaction":"EYE IRRITATION"},{"count":2,"reaction":"FALL"},{"count":2,"reaction":"GASTROOESOPHAGEAL REFLUX DISEASE"},{"count":2,"reaction":"PAIN"},{"count":2,"reaction":"PAIN IN EXTREMITY"},{"count":2,"reaction":"TREMOR"},{"count":2,"reaction":"TYPE 2 DIABETES MELLITUS"}],"_approvalHistory":[],"publicationCount":75,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cequa","Restasis Eye Drops","Tisporin Eye Drops","Ikervis","Cyclosporine"],"phase":"marketed","status":"active","brandName":"CycloSPORINE Ophthalmic","genericName":"CycloSPORINE Ophthalmic","companyName":"Université de Sherbrooke","companyId":"universit-de-sherbrooke","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cyclosporine is a calcineurin inhibitor that suppresses T-cell activation and reduces inflammatory cytokine production in the eye. Used for Dry eye disease (keratoconjunctivitis sicca), Ocular surface inflammation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}